IRIS
DEL PRINCIPE, MARIA ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 33.119
AS - Asia 4.667
EU - Europa 4.287
SA - Sud America 873
AF - Africa 67
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 12
Totale 43.046
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 32.969
SG - Singapore 2.335
IT - Italia 1.212
CN - Cina 914
DE - Germania 787
BR - Brasile 736
HK - Hong Kong 626
IE - Irlanda 486
UA - Ucraina 435
RU - Federazione Russa 333
GB - Regno Unito 278
VN - Vietnam 195
KR - Corea 187
FI - Finlandia 147
FR - Francia 144
SE - Svezia 110
NL - Olanda 104
CA - Canada 99
IN - India 81
PL - Polonia 73
AT - Austria 48
AR - Argentina 47
JP - Giappone 47
ID - Indonesia 44
ES - Italia 41
MX - Messico 38
BD - Bangladesh 29
TR - Turchia 26
ZA - Sudafrica 26
BE - Belgio 24
IR - Iran 23
CO - Colombia 22
PH - Filippine 21
PK - Pakistan 20
AU - Australia 18
UZ - Uzbekistan 18
IQ - Iraq 17
EC - Ecuador 15
CZ - Repubblica Ceca 12
TH - Thailandia 12
VE - Venezuela 12
CL - Cile 11
IL - Israele 11
LT - Lituania 11
SA - Arabia Saudita 11
MA - Marocco 10
PE - Perù 10
PY - Paraguay 10
AE - Emirati Arabi Uniti 8
EG - Egitto 8
MY - Malesia 8
UY - Uruguay 8
CH - Svizzera 7
EU - Europa 7
DZ - Algeria 6
LB - Libano 6
TN - Tunisia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
AZ - Azerbaigian 5
TW - Taiwan 5
DO - Repubblica Dominicana 4
NO - Norvegia 4
RO - Romania 4
RS - Serbia 4
AL - Albania 3
GR - Grecia 3
HR - Croazia 3
KE - Kenya 3
LI - Liechtenstein 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
CR - Costa Rica 2
HN - Honduras 2
KG - Kirghizistan 2
MN - Mongolia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
OM - Oman 2
QA - Qatar 2
BA - Bosnia-Erzegovina 1
BJ - Benin 1
BO - Bolivia 1
CY - Cipro 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
GT - Guatemala 1
HU - Ungheria 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MU - Mauritius 1
Totale 43.040
Salva come PNG Salva come JPEG
Città #
Woodbridge 9.113
Wilmington 8.874
Houston 5.161
Fairfield 1.320
Singapore 1.170
Chandler 975
Ashburn 841
Ann Arbor 731
Hong Kong 610
Seattle 539
Beijing 473
Cambridge 464
Dublin 406
Rome 380
Jacksonville 352
New York 322
Dearborn 288
Medford 288
Santa Clara 257
Dallas 194
Los Angeles 171
The Dalles 147
Lawrence 135
Boardman 103
Zhengzhou 100
Buffalo 96
Milan 94
San Diego 71
São Paulo 66
Ho Chi Minh City 64
Moscow 64
Council Bluffs 62
Munich 53
Mülheim 52
Nuremberg 49
Menlo Park 47
Warsaw 46
Creede 43
Bologna 40
Brooklyn 39
Chicago 38
London 38
Montreal 38
Redondo Beach 35
Tokyo 35
Engelhard 33
Hanoi 33
Jakarta 33
Toronto 32
Seoul 31
Shanghai 28
Atlanta 27
Lappeenranta 26
Phoenix 26
Redwood City 26
Helsinki 24
Orem 24
Guangzhou 23
Boston 22
Brussels 22
Hefei 22
Frankfurt am Main 21
Palo Alto 21
Stockholm 21
Vienna 21
Columbus 20
Norwalk 20
Belo Horizonte 18
Denver 18
Poplar 18
Rio de Janeiro 18
University Park 17
Center 16
Johannesburg 16
San Francisco 16
Turku 16
Verona 16
Turin 15
Campinas 14
Chennai 14
Nanjing 14
Da Nang 13
Falls Church 13
Kraków 13
Kunming 13
Mexico City 13
Shenzhen 13
Amsterdam 12
Bari 12
Bang Bai Mai 11
Florence 11
Naples 11
Porto Alegre 11
Redmond 11
Elk Grove Village 10
Kilburn 10
Manila 10
Mumbai 10
Saint Petersburg 10
Brasília 9
Totale 35.482
Salva come PNG Salva come JPEG
Nome #
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 588
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 513
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 488
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 458
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 457
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 456
Clinical significance of CD38 expression in chronic lymphocytic leukemia 454
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 448
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 441
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 430
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. 430
Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study 427
Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia 421
A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia 419
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 418
Lack of efficacy of imiquimod in patients with basal cell carcinoma previously treated with rituximab for B cell lymphoma: two case reports 418
Advances in the treatment of elderly and frail patients with acute myeloid leukemia 413
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 413
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 412
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage 412
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia 411
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 411
ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations 409
Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23(+)/MLL+ translocation in leukaemia 407
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation 403
Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia 402
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. 401
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia 401
Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes 400
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 397
Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey 397
Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells 394
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma 394
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 391
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study 389
Monitoring of minimal residual disease in acute myeloid leukemia 384
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow 383
High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma 382
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications 380
The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia 377
Circulating regulatory T cells in clinical monoclonal B-cell lymphocytosis. 377
The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells 375
Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. 374
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy 374
Treatment of Acute Myeloid Leukemia with 20-30% Bone Marrow Blasts 372
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia 372
Treatment of low-blast count AML using hypomethylating agents 372
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome 371
A cluster of Geotrichum clavatum (Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature 368
Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia 367
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features 363
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 362
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 361
Minimal Residual Disease as Biomarker for Optimal Biologic Dosing of ARA-C in Patients with Acute Myeloid Leukemia 360
Extensive toxic epidermal necrolysis following brentuximab vedotin administration 359
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. 358
Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia 357
Successful treatment of disseminated fusariosis with high dose liposomal amphotericin-B in a patient with acute lymphoblastic leukemia [4] 352
Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia 351
Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia 351
Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia 348
Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia 347
CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias 345
Thrombosis in adult patients with acute leukemia 343
Longitudinal detection of DNMT3AR882Htranscripts in patients with acute myeloid leukemia 342
Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia 339
Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients: can it be used without measurement of plasma concentration? 338
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia 337
Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia 335
Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. 334
Apoptosis and immaturity in acute myeloid leukemia 334
CD69 is independently prognostic in chronic lymphocytic leukemia: acomprehensive clinical and biological profiling study 332
Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy 331
Circulating regulatory T cells in "clinical" monoclonal B-cell lymphocytosis 331
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia 330
Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia. 329
Risk allocation of adults patients with non-M3 acute myeloid leukemia 325
Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient 320
Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes 319
Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. 317
In vitro elimination of EGFR-overexpressing cancer cells by CD32A chimeric receptor T cells in combination with cetuximab or panitumumab 317
Minimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology? 307
Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling 299
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 291
Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the campus all network 288
Fludarabine, Cytarabine and Gentuzumab Ozogamicin (FLA-GO) as Salvage Therapy and Bridge to Transplant in Adult Relapsed Acute Myeloid Leukemia (AML) Patients 287
FCγ chimeric receptor-engineered T cells: Methodology, advantages, limitations, and clinical relevance 284
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study 279
The emerging role of measurable residual disease detection in AML in morphologic remission 276
Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse 270
Gemtuzumab ozogamicin in combination with intensive chemotherapy for relapsed/refractory acute myeloid leukemia 266
Real-life analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study 265
Case report: A Saprochaete clavata (Magnusiomyces clavatus) severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma 227
An evaluation of enasidenib for the treatment of acute myeloid leukemia 225
Rhodotorula infection in haematological patient: Risk factors and outcome 204
Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness 199
Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases 196
Central nervous system fungal infections in allogeneic stem cell transplantation. Outcome of 24 recent cases and literature review 194
Clinical relevance of an objective - limit of detection - limit of quantification - based flow cytometry approach for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial 192
Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells 191
Totale 35.858
Salva come PNG Salva come JPEG
Categoria #
all - tutte 121.055
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 121.055
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.491 0 0 0 0 0 548 718 554 166 196 233 76
2021/20221.672 62 172 46 48 33 171 100 113 139 165 92 531
2022/20232.622 286 230 230 261 157 472 301 163 285 46 134 57
2023/20241.224 104 52 135 36 99 333 57 83 43 31 35 216
2024/20254.659 182 895 532 246 86 288 403 209 488 473 395 462
2025/20264.005 862 420 994 693 874 162 0 0 0 0 0 0
Totale 43.873